ClinicalTrials.gg
Not yet recruitingNCT07676006Updated Sep 11, 2026

A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

An Early Phase 1 interventional study of GT737 Injection in Relapsed/Refractory Acute Myeloid Leukemia (AML), sponsored by Grit Biotechnology. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Grit Biotechnology · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 264 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Planned enrollment
264th of 433
36 · median 50
Started
2027
with 2 others
Phase 1
121 of 473
69 open now
Primary completion
2030-06
later than 281 of 288 live
Registered
456th of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 264th largest by planned enrollment of the 433 interventional ones that give a count, is one of 3 that started in 2027, is one of 121 in phase 1, reaches primary completion later than 281 of the 288 other live ones, and was the 456th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 814 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

264 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

259 more — sign in →

All 264 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 619 Leukemia, Myeloid, Acute studies recruiting now, 360 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

This is a single-arm, open-label, dose-escalation, prospective exploratory clinical study intended to evaluate the safety, efficacy and cellular pharmacokinetics of GT737 cells in adult patients with relapsed/refractory acute myeloid leukemia (AML).

03

Conditions studied

  • Relapsed/Refractory Acute Myeloid Leukemia (AML)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Voluntarily participate in this clinical study, fully understand the study content, sign the form, and be willing to comply with all study procedures and complete all follow-up visits.
  • 2. Aged between 18 and 75 years old (inclusive), with no restriction on gender.
  • 3. Confirmed diagnosis of acute myeloid leukemia (AML) per the 2016 WHO Classification, with the specific definitions as follows:

Confirmed AML with bone marrow blasts ≥5% at screening, and meeting any one of the following criteria:

  • Relapsed disease: Relapse after achieving complete remission (CR) or complete remission with incomplete hematologic recovery (CRi) following standard induction chemotherapy;
  • Refractory disease: a) Failure to achieve CR/CRi after 2 cycles of induction chemotherapy; b) Relapse within 12 months of first remission with no response to subsequent re-treatment; c) Relapse after or allogeneic hematopoietic stem cell transplantation; d) Failure to achieve CR/CRi after at least two lines of salvage therapy.

    • 4. Confirmed positive expression of CD33 or CD70 via flow cytometry and/or immunohistochemistry.
    • 5. (ECOG) performance status score of 0 or 1.
    • 6. Estimated survival of more than 12 weeks.
    • 7. Toxicities resulting from prior therapies must be stabilized and recovered to Grade ≤1 (alopecia and other toxicities with no significant clinical impact are excluded).
    • 8. Adequate hepatic, renal, pulmonary and cardiac function, meeting the following specific criteria:
    • o Estimated (calculated via the Cockcroft-Gault formula) ≥60 mL/min;
    • o Serum /aspartate aminotransferase (ALT/AST) ≤2.5 times the (ULN);
    • o Total ≤1.5 mg/dL (participants with Gilbert's syndrome excluded from this criterion);
    • o Cardiac ≥50%, no evidence of pleural effusion on echocardiogram (ECHO), and no abnormalities on (ECG);
    • o Absence of clinically significant pleural effusion;
    • o Baseline oxygen saturation >92% while breathing room air.
    • 9. Females of : Serum or urine pregnancy test negative at screening (subjects with surgical sterilization or menopause for ≥2 years are not considered of childbearing potential). Must agree to use highly effective and reliable for 1 year after receiving study treatment, and refrain from oocyte donation.
    • 10. Male participants: If sexually active with females of childbearing potential, must agree to use highly effective and reliable contraception for 1 year after receiving study treatment, and refrain from sperm donation.

Exclusion criteria

Exclusion Criteria:

  • 1. Prior history of central nervous system (CNS) leukemia; or intracranial magnetic resonance imaging (MRI)/PET-CT at screening suggestive of CNS leukemia; or malignant cells identified in cerebrospinal fluid (CSF).
  • 2. Other untreated malignant neoplasms diagnosed within the past 5 years or concurrent (Exceptions: adequately treated cervical carcinoma in situ, localized cutaneous squamous cell carcinoma, basal cell carcinoma, localized prostate cancer, ductal carcinoma in situ of the breast, urothelial carcinoma ≤T1; participants with prostate cancer under active surveillance are eligible).
  • 3. Prior receipt of CD33- or CD70-targeted cellular therapies including CAR-T, NK or iNKT cells (Excluding subjects previously treated with GT737 who qualify for re-treatment).
  • 4. Systemic administered within 7 days prior to cell infusion (Exceptions: inhaled corticosteroids and subjects with prior transplantation history).
  • 5. History of to any component of products to be used in this study, including but not limited to GT737 cell infusion product, cyclophosphamide and fludarabine.
  • 6. Uncontrolled suspected or confirmed fungal, bacterial, viral or other infections, or infections requiring intravenous (IV) antimicrobial therapy (Excluding prophylactic antimicrobial treatment).

    7. Positive test results for any of the following: (HIV) antibody, Treponema pallidum antibody, cytomegalovirus IgM (CMV-IgM), Epstein-Barr virus IgM (EBV-IgM).

  • 8. Active (positive HBV-DNA) and/or active (positive HCV RNA).

Participants positive for HBsAg/HBcAb must undergo HBV-DNA testing; those with negative HBV-DNA may be enrolled. Post-enrollment, prophylactic antiviral therapy shall be administered if clinically indicated per investigator assessment.

Subjects with negative HCV antibody are eligible for enrollment. Participants with positive HCV antibody must receive HCV RNA testing and may be enrolled only if HCV RNA is negative.

  • 9. Presence of any indwelling line or drainage tube (Exceptions: dedicated central venous access catheters such as Port-a-Cath and Hickman catheter).
  • 10. Current or prior central nervous system disorders including seizures, cerebral ischemic/hemorrhagic events, dementia, cerebellar disease, or any disease involving the CNS.
  • 11. Cardiac involvement secondary to acute myeloid leukemia.
  • 12. Occurrence of any of the following within 6 months prior to signing the form:

    • Uncontrolled congestive heart failure ( Class III-IV), angina pectoris, myocardial infarction, cardiomyopathy;
    • Stroke (Excluding lacunar infarction), coronary or peripheral artery bypass graft surgery;
    • arrhythmias (e.g., ventricular arrhythmia), markedly prolonged (corrected QTc ≥500 ms by Bazett's formula, as judged by the investigator);
    • Uncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg), uncontrolled diabetes mellitus;
    • Pulmonary embolism, diffuse pulmonary infiltrates, impaired pulmonary function;
    • Other medical conditions deemed unsuitable for study participation by the investigator.
  • 13. Anticipated or potential need for emergency treatment within 6 weeks due to ongoing or imminent oncologic emergencies (e.g., tumor mass effect, tumor lysis syndrome).
  • 14. Primary immunodeficiency disorders.
  • 15. History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months before enrollment requiring systemic anticoagulation therapy.
  • 16. Any medical condition that may interfere with the assessment of safety or efficacy of the study treatment.
  • 17. or mRNA vaccines administered within 8 weeks prior to lymphodepleting conditioning; inactivated vaccines administered within 4 weeks prior to lymphodepleting conditioning.
  • 18. Females of who are pregnant or breastfeeding (Subjects with surgical sterilization or menopause for ≥2 years are not regarded as of childbearing potential).
  • 19. Male or female participants unwilling to use measures from the time of informed consent through 6 months after completion of study treatment.
  • 20. Participants judged by the investigator to be unlikely to complete all study visits and procedures (including follow-up) or unable to comply with study participation requirements.
  • 21. History of autoimmune disease within the past 2 years causing end-organ damage or requiring systemic agents/systemic disease-modifying therapy (e.g., Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, etc.).
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    GT737 Injection treatment group

    GT737 Injection

    Biological: GT737 Injection

Interventions

  • BiologicalGT737 Injection

    GT737 Injection

06

What researchers measure

Primary outcomes

  1. Proportion of participants experiencing dose limiting toxicity

    The proportion of participants with dose-limiting toxicity (DLT) occurring within 28 days after infusion

    Time frame: 28 days

  2. Adverse Events (AEs) occurring after infusion and their proportions

    Adverse Events (AEs) occurring after infusion and their proportions

    Time frame: 28 days

  3. Severity of Adverse Events (AEs) after infusion

    Assess the severity of Adverse Events (AEs) within 28 days after infusion

    Time frame: 28 days

  4. Compare the differences in safety and tolerability between different treatment subgroups (monotherapy and combination with sirolimus).

    Difference in the incidence and severity of DLT among different treatment subgroups (monotherapy and combination with sirolimus)

    Time frame: 28 Days

Secondary outcomes

  1. Pharmacokinetic parameters: Time to peak expansion (Tmax)after GT737 infusion

    Monitor the time to peak expansion (Tmax)after GT737 infusion.

    Time frame: 28 Days

  2. Pharmacokinetic parameters: peak expansion(Cmax) after GT737 infusion

    Monitor the peak expansion(Cmax) after GT737 infusion.

    Time frame: 28 Days

  3. Pharmacokinetic parameters: area under the curve (AUC) after GT737 infusion

    Monitor the area under the curve (AUC) after GT737 infusion.

    Time frame: 28 Days

  4. Pharmacokinetic parameters: survival duration after GT737 infusion

    Monitor the survival duration after GT737 infusion.

    Time frame: 12 months after infusion

  5. Pharmacokinetic parameters: differences in Time to peak expansion (Tmax)of GT737 cells across different treatment subgroups

    Assess the differences in Time to peak expansion (Tmax)of GT737 cells across different treatment subgroups

    Time frame: 28 Days

  6. Pharmacokinetic parameters: differences in peak expansion(Cmax)of GT737 cells across different treatment subgroups

    Assess the differences in peak expansion(Cmax)of GT737 cells across different treatment subgroups

    Time frame: 28 Days

  7. Pharmacokinetic parameters: differences in area under the curve (AUC) of GT737 cells across different treatment subgroups

    Assess the differences in area under the curve (AUC) of GT737 cells across different treatment subgroups

    Time frame: 28 Days

  8. Pharmacokinetic parameters: differences in survival duration of GT737 cells across different treatment subgroups

    Assess the differences in survival duration of GT737 cells across different treatment subgroups

    Time frame: 12 months after infusion

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2027; primary completion for Jun 2030, 37 months later.

Of 182 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's planned 37 months is close to that.

Counting every sponsor, half of 490 studies reached it within 49 months; a quarter within 31 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jun 30, 2026
StartEst.
May 2027
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2030
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07676006
Lead sponsor
Grit Biotechnology
Collaborators
Shenzhen People's Hospital
Responsible party
Sponsor
First posted
Jun 30, 2026
Start date
May 2027 (estimated)
Primary completion
Jun 2030 (estimated)
Completion
Jun 2030 (estimated)
Last update
Sep 11, 2026

Study contacts

Jihao Zhou
Contact
zhoujihao@aliyun.com
+86 15000901110

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion